

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>UBS Oncology Impact Fund L.P.</u> (Last) (First) (Middle) UBS TRUSTEES (CAYMAN) LTD 5TH FL CAYMAN CORP CENTER 27 HOSPITAL (Street) GEORGE TOWN E9 KY1-1106 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Oncorus, Inc. [ONCR]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 10/06/2020	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/06/2020		C		1,525,348	A	(I)	1,525,348	D ⁽²⁾⁽³⁾	
Common Stock	10/06/2020		C		700,453	A	(I)	2,225,801	D ⁽²⁾⁽³⁾	
Common Stock	10/06/2020		P		151,224	A	\$15	2,377,025	D ⁽²⁾⁽³⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A-1 Preferred Stock	(I)	10/06/2020		C		1,525,348		(I)	(I)	Common Stock	1,525,348	\$0.00	0	D ⁽²⁾⁽³⁾	
Series B Preferred Stock	(I)	10/06/2020		C		700,453		(I)	(I)	Common Stock	700,453	\$0.00	0	D ⁽²⁾⁽³⁾	

1. Name and Address of Reporting Person*
UBS Oncology Impact Fund L.P.

 (Last) (First) (Middle)
 UBS TRUSTEES (CAYMAN) LTD
 5TH FL CAYMAN CORP CENTER 27 HOSPITAL

 (Street)
 GEORGE TOWN E9 KY1-1106

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Oncology Impact Fund (Cayman) Management L.P.

 (Last) (First) (Middle)
 UBS TRUSTEES (CAYMAN) LTD
 5TH FL CAYMAN CORP CENTER 27 HOSPITAL

 (Street)
 GEORGE TOWN E9 KY1-1106

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
MPM Oncology Impact Management GP LLC

 (Last) (First) (Middle)
 C/O MPM ASSET MANAGEMENT LLC

450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person*

MPM Oncology Impact Management LP

(Last) (First) (Middle)

C/O MPM ASSET MANAGEMENT LLC
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

Explanation of Responses:

1. Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.
2. The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
3. The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Remarks:

/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P 10/08/2020

/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P. 10/08/2020

/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC 10/08/2020

/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP 10/08/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.